Scholarlink

Background <p>The escalating threat of antibiotic resistance, along with the global rise in cancer incidence and oxidative stress-related disorders, underscores the urgent need for a continuous identification of novel antimicrobial drugs, anticancer treatments, and antioxidant compounds. Actinomycetes isolated from soil are recognized for generating secondary metabolites with novel bioactivities, including antioxidant, antimicrobial, and anticancer properties.</p> Results <p>Molecular identification revealed that the predominant isolate belonged to the <i>Streptomyces enissocaesilis</i> SMS712 (Accession number PV464955). The <i>S. enissocaesilis</i> SMS712 extract demonstrated notable antibacterial activity, showing the highest inhibition zone (14.33 ± 1.53&#xa0;mm) against <i>Escherichia coli</i>, while no antifungal activity was detected against the tested fungal species. The <i>S. enissocaesilis</i> SMS712 extract showed moderate antioxidant activity, ranging from 37% to 53.3%. Anticancer activity was evaluated against two cell lines, MCF-7 and HCT-16, yielding IC<sub>50</sub> values ranging from 21.9&#xa0;µg/mL to 59.2&#xa0;µg/mL. TLC separation followed by ¹H NMR analysis revealed four bioactive compounds from <i>S. enissocaesilis</i> SMS712 with antimicrobial, anticancer, and antioxidant activities. The identified compounds − 2-Methylhexadecan-1-ol, (Z)-13-Docosenamide, 2-Ethyl-2-(hydroxymethyl)propane-1,3-diol, and (Z)-9-Octadecenoic acid - were further supported by molecular docking analyses, suggesting their therapeutic mechanisms.</p> Conclusions <p>This study highlights <i>S. enissocaesilis</i> SMS712 as a promising source for novel agents against antibiotic resistance, oxidative stress, and cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolation, identification, and bioactivity evaluation of novel metabolites from soil-derived actinomycetes with antimicrobial, antioxidant, and anticancer potential: in silico molecular docking insights

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月2日

查看全文
  • Mona M. Soliman,
  • Mahmoud Ibrahim,
  • Mohamed A. Dawoud,
  • Toqa S. Mohamed,
  • Sayed M. S. Abo El-Souad

摘要

Background

The escalating threat of antibiotic resistance, along with the global rise in cancer incidence and oxidative stress-related disorders, underscores the urgent need for a continuous identification of novel antimicrobial drugs, anticancer treatments, and antioxidant compounds. Actinomycetes isolated from soil are recognized for generating secondary metabolites with novel bioactivities, including antioxidant, antimicrobial, and anticancer properties.

Results

Molecular identification revealed that the predominant isolate belonged to the Streptomyces enissocaesilis SMS712 (Accession number PV464955). The S. enissocaesilis SMS712 extract demonstrated notable antibacterial activity, showing the highest inhibition zone (14.33 ± 1.53 mm) against Escherichia coli, while no antifungal activity was detected against the tested fungal species. The S. enissocaesilis SMS712 extract showed moderate antioxidant activity, ranging from 37% to 53.3%. Anticancer activity was evaluated against two cell lines, MCF-7 and HCT-16, yielding IC50 values ranging from 21.9 µg/mL to 59.2 µg/mL. TLC separation followed by ¹H NMR analysis revealed four bioactive compounds from S. enissocaesilis SMS712 with antimicrobial, anticancer, and antioxidant activities. The identified compounds − 2-Methylhexadecan-1-ol, (Z)-13-Docosenamide, 2-Ethyl-2-(hydroxymethyl)propane-1,3-diol, and (Z)-9-Octadecenoic acid - were further supported by molecular docking analyses, suggesting their therapeutic mechanisms.

Conclusions

This study highlights S. enissocaesilis SMS712 as a promising source for novel agents against antibiotic resistance, oxidative stress, and cancer.

Graphical abstract